Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride can help treat men's hair loss but may have side effects.

This report verifies isotretinoin's significant efficacy in treating severe acne over the past year in the U.S., highlighting the need for careful patient selection and monitoring due to potential side effects.

In this study, topical phenylephrine significantly reduced hair shedding and increased the force needed to pluck hair in women undergoing cosmetic procedures, suggesting its potential utility for traction alopecia.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

In this study, trilostane was generally effective and well-tolerated for treating canine Cushing's syndrome, though some dogs experienced signs of hypoadrenocorticism, and dose adjustments were necessary over time.

In this case study, ischemic stroke occurred in a 20-year-old male taking finasteride for hair loss, with multiple genetic predispositions for thrombosis; while causality is uncertain, clinicians should exercise caution when prescribing finasteride to patients with thrombotic risk factors.

Current evidence reviewed in this study indicates that finasteride, a drug for hair loss, can cause depression and suicidality, with delayed recognition partly due to insufficient post-approval pharmacovigilance by manufacturers and regulators.

Ebastine may help regrow hair in alopecia areata patients.

This article describes SAHA syndrome, which includes symptoms of nodulocystic or severe acne, female pattern hair loss, and hirsutism, but reports no new results.

This report suggests that fluvoxamine use may be associated with hair loss, as observed in a 28-year-old male whose condition improved after stopping the drug.

In this case report, a 75-year-old man with benign essential blepharospasm and Parkinson disease experienced significant symptom relief from dystonia after starting finasteride, suggesting it may be a potential therapeutic option.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

In this study on male rats, parachlorophenylalanine treatment induced hypersexual behavior and hair loss linked to increased social interaction but had no effect on brain serotonin when testosterone was used instead.

This study found that 308 nm excimer lamp therapy provides a good clinical response with fewer adverse effects for limited alopecia areata but is less effective for widespread hair loss like alopecia totalis.

This study found that valproic acid is effective in controlling absence seizures and can improve other seizure types, but 20% of patients experience mostly transient adverse reactions.

This study found that 5 mg/day oral finasteride was effective and safe for improving hair outcomes in normoandrogenic postmenopausal women with androgenetic alopecia over 18 months.

In this study, researchers identified several active metabolites in Eclipta alba, demonstrated strong interaction with Alzheimer's disease proteins, and found that 28 days of treatment improved memory without significant toxicity in rats, suggesting potential pathways for treating Alzheimer's.

This case study indicates that older patients with NMOSD may show favorable clinical improvements with aggressive treatment, even when the intervention is initiated later in the disease course.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study's supplementary materials provide retrospective data on the safety and tolerability of combining spironolactone and low-dose minoxidil for treating hair loss in adult females, but no new results are directly reported.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

This study observed that upadacitinib demonstrated significant efficacy and favorable safety for treating alopecia areata over 12 months in a real-world setting, with patients having an atopic background showing better early response; no serious adverse events were reported.

This study found that low dose valproate monotherapy in epileptic children commonly leads to side-effects like weight gain and decreased appetite, especially among younger patients.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.